David D. Aufhauser

David D. Aufhauser

Auto-generated profile, based on publicly available information

David D. Aufhauser

Department of Surgery, University of Wisconsin, United States

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in Nature
Verified
Journal Article
Open access
PDF file
RARanjith P. Anand
Ranjith P. Anand
JLJacob V. Layer
Jacob V. Layer
DHDavid Heja
David Heja
THTakayuki Hirose
Takayuki Hirose
GLGrace Lassiter
Grace Lassiter
WQWenning Qin
Wenning Qin
Recent human decedent model studies1,2 and compassionate xenograft use3 have explored the promise of porcine organs for human transplantation. To proceed to human studies, a clinically ready porcine donor must be engineered and its xenograft successfully tested in nonhuman primates. Here we describe the design, creation and long-term life-supporting function of kidney grafts from a genetically engineered porcine donor transplanted into a cynomolgus monkey model. The porcine donor was engineered to carry 69 genomic edits, eliminating glycan antigens, overexpressing human transgenes and inactivating porcine endogenous retroviruses. In vitro functional analyses showed that the edited kidney endothelial cells modulated inflammation to an extent that was indistinguishable from that of human endothelial cells, suggesting that these edited cells acquired a high level of human immune compatibility. When transplanted into cynomolgus monkeys, the kidneys with three glycan antigen knockouts alone experienced poor graft survival, whereas those with glycan antigen knockouts and human transgene expression demonstrated significantly longer survival time, suggesting the benefit of human transgene expression in vivo. These results show that preclinical studies of renal xenotransplantation could be successfully conducted in nonhuman primates and bring us closer to clinical trials of genetically engineered porcine renal grafts.

18 April 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DADavid D. Aufhauser
David D. Aufhauser
ZWZhonglin Wang
Zhonglin Wang
DMDouglas R. Murken
Douglas R. Murken
TBTricia R. Bhatti
Tricia R. Bhatti
YWYanfeng Wang
Yanfeng Wang
MLMatthew H. Levine
Matthew H. Levine
Experimentally, females show an improved ability to recover from ischemia-reperfusion injury (IRI) compared with males; however, this sex-dependent response is less established in humans. Here, we developed a series of murine renal ischemia and transplant models to investigate sex-specific effects on recovery after IRI. We found that IRI tolerance is profoundly increased in female mice compared with that observed in male mice and discovered an intermediate phenotype after neutering of either sex. Transplantation of adult kidneys from either sex into a recipient of the opposite sex followed by ischemia at a remote time resulted in ischemia recovery that reflected the sex of the recipient, not the donor, revealing that the host sex determines recovery. Likewise, renal IRI was exacerbated in female estrogen receptor α–KO mice, while female mice receiving supplemental estrogen before ischemia were protected. We examined data from the United Network for Organ Sharing (UNOS) to determine whether there is an association between sex and delayed graft function (DGF) in patients who received deceased donor renal transplants. A multivariable logistic regression analysis determined that there was a greater association with DGF in male recipients than in female recipients. Together, our results demonstrate that sex affects renal IRI tolerance in mice and humans and indicate that estrogen administration has potential as a therapeutic intervention to clinically improve ischemia tolerance.

23 February 2015 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MLM. H. Levine
M. H. Levine
ZWZ. Wang
Z. Wang
TBT. R. Bhatti
T. R. Bhatti
YWYanfeng Wang
Yanfeng Wang
DAD. D. Aufhauser
D. D. Aufhauser
WHW. W. Hancock
W. W. Hancock
Renal ischemia‐reperfusion injury (IRI) is a common cause of renal dysfunction and renal failure. Histone/protein deacetylases (HDACs) regulate gene accessibility and higher order protein structures and may alter cellular responses to a variety of stresses. We investigated whether use of pan‐ and class‐specific HDAC inhibitors (HDACi) could improve IRI tolerance in the kidney. Using a model of unilateral renal IRI, we investigated early renal function after IRI, and calculated fibrosis after IRI using an automated scoring system. We found that pan‐HDAC inhibition using trichostatin (TSA) yielded significant renal functional benefit at 24–96 hours (p < 0.001). Treated mice developed significantly less fibrosis at 30 days (p < 0.0004). Class I HDAC inhibition with MS‐275 yielded similar effects. Protection from fibrosis formation was also noted in a cold ischemia transplant model (p < 0.008) with a trend toward improved cold ischemic survival in TSA‐treated mice. These effects were not accompanied by induction of typical ischemic tolerance pathways or by priming of heat shock protein expression. In fact, heat shock protein 70 deletion or overexpression did not alter renal ischemia tolerance. Micro‐RNA 21, known to be enhanced in vitro in renal tubular cells that survive stress, was enhanced by treatment with HDACi, pointing to possible mechanism.

1 September 2012 in Journal of Surgical Research
Verified
Journal Article
Closed access
PMPaul R. Massey
Paul R. Massey
JSJoseph V. Sakran
Joseph V. Sakran
AMAngela M. Mills
Angela M. Mills
BSBabak Sarani
Babak Sarani
DADavid D. Aufhauser
David D. Aufhauser
DHDaniel N. Holena
Daniel N. Holena

15 April 2018 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
DADavid D. Aufhauser
David D. Aufhauser
APAllison W. Peng
Allison W. Peng
DMDouglas R. Murken
Douglas R. Murken
SCSeth J. Concors
Seth J. Concors
PAPeter L. Abt
Peter L. Abt
MLMatthew H. Levine
Matthew H. Levine

27 December 2012 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
DADavid D. Aufhauser
David D. Aufhauser
TRTom Rose
Tom Rose
MLMatthew Levine
Matthew Levine
RBRebecca Barnett
Rebecca Barnett
EOE. Andrew Ochroch
E. Andrew Ochroch
PAPeter L. Abt
Peter L. Abt